FDA: Biosimilar Labeling Should Rely On Innovator Data
This article was originally published in Scrip
Executive Summary
The labeling for biosimilars should rely largely on the relevant safety and effectiveness data used by the corresponding US-licensed innovator medicines, with appropriate product-specific modifications, the FDA said in a new long-awaited draft guidance document issued on March 31 – declaring that's the best approach the agency could come up with after six years of trying.
You may also be interested in...
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.